298 related articles for article (PubMed ID: 21654256)
21. From guaiac to immune fecal occult blood tests: the emergence of technology in colorectal cancer screening.
Greenwald B
Gastroenterol Nurs; 2005; 28(2):90-6. PubMed ID: 15832108
[TBL] [Abstract][Full Text] [Related]
22. The immunochemical faecal occult blood test leads to higher compliance than the guaiac for colorectal cancer screening programmes: a cluster randomized controlled trial.
Federici A; Giorgi Rossi P; Borgia P; Bartolozzi F; Farchi S; Gausticchi G
J Med Screen; 2005; 12(2):83-8. PubMed ID: 15949119
[TBL] [Abstract][Full Text] [Related]
23. Colonoscopy-controlled intra-individual comparisons to screen relevant neoplasia: faecal immunochemical test vs. guaiac-based faecal occult blood test.
Oort FA; Terhaar Sive Droste JS; Van Der Hulst RW; Van Heukelem HA; Loffeld RJ; Wesdorp IC; Van Wanrooij RL; De Baaij L; Mutsaers ER; van der Reijt S; Coupe VM; Berkhof J; Bouman AA; Meijer GA; Mulder CJ
Aliment Pharmacol Ther; 2010 Feb; 31(3):432-9. PubMed ID: 19878150
[TBL] [Abstract][Full Text] [Related]
24. Taishotoyama Symposium Barriers to colorectal cancer screening: economics, capacity and adherence.
Inadomi JM
J Gastroenterol Hepatol; 2008 Dec; 23 Suppl 2():S198-204. PubMed ID: 19120898
[TBL] [Abstract][Full Text] [Related]
25. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia.
Fletcher RH; Ransohoff DF; Imperiale TF
Cancer; 2007 May; 109(9):1925-6; author reply 1926. PubMed ID: 17370313
[No Abstract] [Full Text] [Related]
26. Colorectal cancer screening with the addition of flexible sigmoidoscopy to guaiac-based faecal occult blood testing: a French population-based controlled study (Wintzenheim trial).
Denis B; Gendre I; Aman F; Ribstein F; Maurin P; Perrin P
Eur J Cancer; 2009 Dec; 45(18):3282-90. PubMed ID: 19665368
[TBL] [Abstract][Full Text] [Related]
27. Colorectal cancer screening adherence is higher with fecal immunochemical tests than guaiac-based fecal occult blood tests: a randomized, controlled trial.
Hoffman RM; Steel S; Yee EF; Massie L; Schrader RM; Murata GH
Prev Med; 2010; 50(5-6):297-9. PubMed ID: 20307568
[TBL] [Abstract][Full Text] [Related]
28. [Comparison of different stool tests for the detection of cancer of the colon].
Vogel T; Driemel C; Hauser A; Hansmann A; Lange S; Jonas M; Möslein G
Dtsch Med Wochenschr; 2005 Apr; 130(14):872-7. PubMed ID: 15800820
[TBL] [Abstract][Full Text] [Related]
29. Choice of fecal occult blood tests for colorectal cancer screening: recommendations based on performance characteristics in population studies: a WHO (World Health Organization) and OMED (World Organization for Digestive Endoscopy) report.
Young GP; St John DJ; Winawer SJ; Rozen P;
Am J Gastroenterol; 2002 Oct; 97(10):2499-507. PubMed ID: 12385430
[TBL] [Abstract][Full Text] [Related]
30. Screening for colorectal cancer: which test can we afford?
Lansdorp-Vogelaar I; van Ballegooijen M; Kuipers EJ
Z Gastroenterol; 2008 Apr; 46 Suppl 1():S38-40. PubMed ID: 18368641
[No Abstract] [Full Text] [Related]
31. Evaluation of an immunochemical fecal occult blood test with automated reading in screening for colorectal cancer in a general average-risk population.
Launoy GD; Bertrand HJ; Berchi C; Talbourdet VY; Guizard AV; Bouvier VM; Caces ER
Int J Cancer; 2005 Jun; 115(3):493-6. PubMed ID: 15700317
[TBL] [Abstract][Full Text] [Related]
32. A cost analysis of screening methodology for family members of colorectal cancer patients.
Rozen P; Ron E
Am J Gastroenterol; 1989 Dec; 84(12):1548-51. PubMed ID: 2512809
[TBL] [Abstract][Full Text] [Related]
33. Which colorectal cancer screening test is best?
Mandel JS
J Natl Cancer Inst; 2007 Oct; 99(19):1424-5. PubMed ID: 17895471
[No Abstract] [Full Text] [Related]
34. Cost-effectiveness analysis of colorectal cancer screening strategies in Singapore: a dynamic decision analytic approach.
Wong SS; Leong AP; Leong TY
Stud Health Technol Inform; 2004; 107(Pt 1):104-10. PubMed ID: 15360784
[TBL] [Abstract][Full Text] [Related]
35. [Individual screening for colorectal cancer: which strategy for which patient?].
Demols A; Van Laethem JL; Gay F; Franchimont D; Adler M; Van Gossum A
Rev Med Brux; 2001 Sep; 22(4):A203-9. PubMed ID: 11680174
[TBL] [Abstract][Full Text] [Related]
36. [Improvement in screening for colorectal cancer associated with the use of immunochemical faecal occult blood test].
Launoy G
Pathol Biol (Paris); 2009 Sep; 57(6):488-92. PubMed ID: 18834677
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness analysis of immunochemical occult blood screening for colorectal cancer among three fecal sampling methods.
Yamamoto M; Nakama H
Hepatogastroenterology; 2000; 47(32):396-9. PubMed ID: 10791199
[TBL] [Abstract][Full Text] [Related]
38. Immunochemical faecal occult blood tests are superior to guaiac-based tests for the detection of colorectal neoplasms.
Dancourt V; Lejeune C; Lepage C; Gailliard MC; Meny B; Faivre J
Eur J Cancer; 2008 Oct; 44(15):2254-8. PubMed ID: 18760592
[TBL] [Abstract][Full Text] [Related]
39. Short term outcomes of the first round of a pilot colorectal cancer screening programme with guaiac based faecal occult blood test.
Denis B; Ruetsch M; Strentz P; Vogel JY; Guth F; Boyaval JM; Pagnon X; Ebelin JF; Gendre I; Perrin P
Gut; 2007 Nov; 56(11):1579-84. PubMed ID: 17616542
[TBL] [Abstract][Full Text] [Related]
40. A comparison of fecal occult-blood tests for colorectal-cancer screening.
Allison JE; Tekawa IS; Ransom LJ; Adrain AL
N Engl J Med; 1996 Jan; 334(3):155-9. PubMed ID: 8531970
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]